According to a recent LinkedIn post from Datavant, the company is working with Labcorp and Amazon Web Services to address data fragmentation in Alzheimer’s research. The post highlights Datavant’s role in privacy-preserving connectivity that links diverse real-world datasets, including diagnostic and genomic data, while maintaining security and de-identification.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that this infrastructure allows researchers to connect Labcorp data with claims and other real-world sources, then apply AWS’s AI-driven analytics to identify trial-ready cohorts in minutes. For investors, this may signal Datavant’s deepening integration into high-value clinical research workflows and positions the firm as an enabling data infrastructure player in complex disease research.
If these collaborations scale, Datavant could benefit from increased demand for its connectivity platform across pharmaceutical, diagnostics, and healthcare partners. More broadly, the focus on Alzheimer’s, a major area of unmet clinical need and R&D spend, may enhance the company’s strategic relevance in real-world evidence generation and long-term value creation within the life sciences data ecosystem.